Cardio-oncology最新文献

{"title":"Long-term impact of anthracycline in early-stage breast cancer, bridging of MiRNAs profiler for early cardiotoxicity.","authors":"Nattaya Poovorawan, Thiti Susiriwatananont, Chinachote Teerapakpinyo, Pajaree Chariyavilaskul, Piyada Sitthideatphaiboon, Luxica Jarutasnangkul, Monravee Tumkosit, Pairoj Chattranukulchai, Nonthikorn Theerasuwipakorn, Chatchawit Aporntewan, Shanop Shuangshoti, Sopark Manasnayakorn, Chanida Vinayanuwattikun, Yongkasem Vorasettakarnkij, Virote Sriuranpong","doi":"10.1186/s40959-025-00337-2","DOIUrl":"https://doi.org/10.1186/s40959-025-00337-2","url":null,"abstract":"<p><strong>Background: </strong>Anthracyclines are essential in early breast cancer chemotherapy but pose long-term cardiotoxicity risks.</p><p><strong>Objectives: </strong>This study aims to investigate the long-term incidence of cancer therapy-related cardiac dysfunction (CTRCD), bridging with the miRNAs profiler representing acute cardiac injury.</p><p><strong>Methods: </strong>We conducted a prospective cohort including stage I-III breast cancer patients who received anthracycline between 2007 and 2012. Echocardiography was performed before and 12 weeks after anthracycline administration. The miRNAs profiler was conducted by NanoString and RT-PCR. Long-term cardiac magnetic resonance imaging (CMR) was evaluated in 24.2% of asymptomatic participants.</p><p><strong>Results: </strong>At a median follow-up of 11 [IQR 6-12] years, 194 patients who completed follow-up echocardiography after anthracycline were included in the analysis. The median age at diagnosis was 50 [26-72] years. An early LVEF decline of ≥ 10% was found in 32.9% of participants. The cumulative equivalent dose of doxorubicin was 223.2 ± 21.6 mg/m2. At the time of censoring, sixty-four participants (32.9%) died, 70% from breast cancer. Nine participants (4.6%) reported cardiovascular events compatible with the CTRCD definition. Forty-seven participants (24.2%) underwent long-term cardiac evaluation. The miRNAs profiler and RT-PCR at different time points, 3 weeks and 6 weeks, respectively, revealed significantly diverse expressions of miR-1-3p and miR-16-5p in participants with and without an early LVEF decline of ≥ 10%. Despite cardiac injury demonstrated by dynamic miR-1-3p and miR-16-5p, CMR parameters revealed no significant differences.</p><p><strong>Conclusions: </strong>Our study demonstrates a very low incidence of long-term symptomatic CTRCD. The diverse expression patterns of miR-16-5p and miR-1-3p at different time points also provide valuable biological insights. Within-normal results of an exact and comprehensive CMR, in asymptomatic and any LVEF change participants, indicate the long-term safety of limited-dose anthracycline-containing use.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"11 1","pages":"39"},"PeriodicalIF":3.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary artery calcification score as a prognostic factor in younger patients with multiple myeloma undergoing autologous stem cell therapy.","authors":"Hans-Jonas Meyer, Wolfram Pönisch, Jan Borggrefe, Alexey Surov","doi":"10.1186/s40959-025-00338-1","DOIUrl":"https://doi.org/10.1186/s40959-025-00338-1","url":null,"abstract":"<p><strong>Background: </strong>Coronary artery calcification (CAC) scoring can be performed as a by-product of computed tomography (CT). CAC scoring may reflect the general cardiovascular risk profile of patients. The aim of the present study was to determine the impact of CAC on overall survival (OS) in patients with multiple myeloma (MM).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on all patients with MM undergoing peripheral blood stem cell transplantation between the years 2009 and 2019. A total of 127 patients (50 female patients, 39.4%) with a mean age of 57.8 ± 7.6 years were included in the analysis. A whole-body CT scan was used to assess the CAC score for each patient. The Weston score as a surrogate for Agatston score was applied in the non-gated staging CT images.c RESULTS: A total of 27 patients (22.0%) died during the course of the study. The CAC score did not differ between non-survivors and survivors in the discrimination analysis (mean 1.2 ± 2.4 versus 2.0 ± 2.8, p = 0.13). The CAC score showed no correlation with overall survival, with an HR of 0.92 (95% CI 0.78-1.09, p = 0.35). Of the patients without calcification (CAC score 0, n = 66, 51.9%), 18 died, while of those with calcification (CAC score 1 or higher, n = 61, 48.1%), nine died. The results of the Fisher's exact test showed no statistically significant difference between the two groups (p = 0.20).</p><p><strong>Conclusions: </strong>The presence of CT-defined coronary calcifications does not predict survival in younger patients with multiple myeloma undergoing autologous stem cell therapy and comparably short survival. The impact of CT-defined cardiovascular risk factors appears to be relatively modest in this heterogeneous disease.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"11 1","pages":"38"},"PeriodicalIF":3.2,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of taxane-anthracycline and taxane only treatment on cardiac function in breast cancer-a retrospective cohort study.","authors":"Árpád Kézdi, Emese Szelke, Magdolna Dank, Dorottya Mühl, Gyöngyvér Szentmártoni, Gergely Szabó, Dominic Joseph Fogarasi, István Takács, Viktor J Horváth, Ádám G Tabák","doi":"10.1186/s40959-025-00335-4","DOIUrl":"https://doi.org/10.1186/s40959-025-00335-4","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiotoxic, anthracycline-based therapies have high value in selected patients with breast cancer. We aimed to describe the effect of anthracycline plus taxane and single taxane chemotherapies on echocardiographic parameters in women with breast cancer.</p><p><strong>Methods: </strong>We retrospectively analysed data of 68 women (> 18 years old) treated for breast cancer in 2018-2021 in the Cardiology Outpatient Clinic of Semmelweis University, Department of Internal Medicine and Oncology. Cardiovascular medical history was collected at baseline and transthoracic echocardiography was completed at each visit. Also, we reviewed electronic medical records for other relevant medical information. Measured echocardiography parameters were assigned to five periods (0-14 days, then every half year and beyond day 545) based on the time since the first treatment. Trajectories of ejection fraction and diastolic function associated markers over the follow-up periods were analysed by linear mixed models.</p><p><strong>Results: </strong>Mean age of the anthracycline plus taxane group was 52.7 ± 14.1 years, of the single taxane group 55.2 ± 13.1 years. The mean anthracycline dose was equivalent to 240 mg/m² of doxorubicin. Overall pre-existing cardiovascular burden was low. Statistically significant changes were found only in the anthracycline plus taxane group: ejection fraction decreased mildly from 65.5 ± 3.1% at baseline to 62.1 ± 3.2% at 181-365 days (p = 0.007) while deceleration time decreased mildly from 227.9 ± 33.9 msec to 197.4 ± 29.4 msec at 15-180 days (p = 0.028). Both drops were only temporary and values neared baseline values over follow-up (p = NS vs. baseline). Other important determinants of ejection fraction were age and hypertension among the investigated risk factors.</p><p><strong>Conclusion: </strong>Our study confirms the overall safety on cardiac function of both single taxane and anthracycline plus taxane chemotherapy, as we found no changes in echocardiographic parameters associated with single taxane therapy, while anthracycline plus taxane chemotherapy was associated with a temporary and clinically insignificant reduction of ejection fraction and deceleration time over 1.5 years of follow-up. Our study is limited by its retrospective nature and the low number of participants.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"11 1","pages":"37"},"PeriodicalIF":3.2,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11992891/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hemoglobin A1c stratifies risk of adverse cardiovascular outcomes in prostate cancer survivors in the UK Biobank: a cohort study.","authors":"Adithya K Yadalam, Alexander C Razavi, Sagar A Patel, Chang Liu, Yan V Sun, Anant Mandawat","doi":"10.1186/s40959-025-00330-9","DOIUrl":"https://doi.org/10.1186/s40959-025-00330-9","url":null,"abstract":"<p><p>Cardiovascular mortality is a major cause of death in prostate cancer (PCa) survivors, yet tools for cardiovascular risk stratification in this population are lacking. Although hemoglobin A1c (HbA1c) is routinely utilized for risk stratification in the general population, the value of HbA1c for cardiovascular risk stratification in patients with PCa is unknown. Leveraging data from the UK Biobank, we analyzed the association of HbA1c and adverse cardiovascular outcomes in 2,270 men diagnosed with PCa. Over a median follow-up of 13.4 (IQR 1.7) years, 172 cardiovascular death or non-fatal myocardial infarction (MI) events occurred. When compared to participants with an HbA1c < 5.7% in competing-risk regression analysis accounting for non-cardiovascular death, HbA1c ≥ 6.5% was the strongest predictor of cardiovascular death or non-fatal MI (sHR 1.88, 95% CI 1.01-3.48, P < 0.001) after insulin use in a risk model adjusted for demographics, traditional cardiovascular risk factors, and insulin use. Furthermore, when compared to age-matched male UK Biobank participants without PCa, continuous HbA1c levels were a stronger predictor of adverse cardiovascular outcomes in PCa survivors (P-interaction = 0.011). Our findings highlight HbA1c as a robust predictor of cardiovascular risk in men with PCa. Further prospective studies are needed to discern if improving glycemic control could decrease the risk of adverse cardiovascular outcomes in this population.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"11 1","pages":"36"},"PeriodicalIF":3.2,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983747/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143983107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating cardiovascular diseases related to endocrine therapy in hormone receptor-positive early breast cancer: insights from a nationwide real-world study.","authors":"Cheng Zeng, Hong Li, Wenna Wang, Lixi Li, Binliang Liu, Bo Lan, Qing Li, Wenjing Yang, Jiani Wang, Fei Ma","doi":"10.1186/s40959-025-00333-6","DOIUrl":"https://doi.org/10.1186/s40959-025-00333-6","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) patients face abnormal lipid metabolism and increased cardiovascular disease (CVD) risk due to endocrine therapies (ETs). This study evaluates CVD incidence and lipid abnormalities in Chinese patients with early-stage hormone receptor-positive (HR+) BC to inform personalized treatments.</p><p><strong>Methods: </strong>Data from female patients aged 18-80 years with stage I-III HR + BC registered in the National Cancer Center Oncology Information Database (NCCOID) (2013-2018) were analyzed. Outcomes included lipid profile changes, CVD incidence, and five-year survival rates.</p><p><strong>Results: </strong>Among 11,537 patients, ETs significantly disrupted lipid metabolism, increasing abnormal total cholesterol, triglycerides, LDL-C, and HDL-C levels. Nonsteroidal aromatase inhibitors (NSAI) ± ovarian function suppression (OFS) led to the largest increase in abnormal total cholesterol (10.26 to 17.32%), while selective estrogen receptor modulators (SERM) ± OFS caused the greatest rises in triglycerides (16.07 to 25.86%), LDL-C (12.11 to 23.34%), and HDL-C (10.86 to 17.23%). Only 3.82% of patients received lipid-lowering therapy. ETs were associated with higher CVD incidence, including hypertension, myocardial infarction, and atrial fibrillation, but five-year survival rates did not differ significantly across ET regimens (P > 0.05).</p><p><strong>Conclusion: </strong>ETs may be associated with alterations in lipid metabolism and a potential increase in CVD risk in early-stage HR + BC patients. These findings highlight the relevance of enhanced lipid monitoring and cardiovascular risk management to support optimized treatment outcomes in the Chinese population.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"11 1","pages":"35"},"PeriodicalIF":3.2,"publicationDate":"2025-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating modifiable risk factors associated with ideal cardiovascular health among cancer survivors: a scoping review.","authors":"Wing Lam Tock, Yujia Tang, Lise Gauvin","doi":"10.1186/s40959-025-00329-2","DOIUrl":"10.1186/s40959-025-00329-2","url":null,"abstract":"<p><strong>Background: </strong>Cancer survivors are at higher risk of developing cardiovascular diseases and face worse morbidity and mortality outcomes than the general population. The American Heart Association (AHA) introduced the Life's Essential 8 framework, encompassing eight modifiable risk factors and lifestyle behaviors for maintaining ideal cardiovascular health (CVH). Although this framework is well-established for predicting CVH in the general population, studies on its association with cardiovascular outcomes among cancer survivors remain scattered across the literature.</p><p><strong>Objective: </strong>This review maps existing literature surrounding modifiable risk factors, lifestyle behaviors, CVH, and cardiovascular outcomes among cancer survivors to take stock of what is known, identify methodological strengths and weaknesses, and propose promising research directions.</p><p><strong>Methods: </strong>A scoping review was conducted to identify studies examining different dimensions of ideal CVH in adult cancer survivors. Measurement methods of ideal CVH metrics, and determinants associated with CVH were examined.</p><p><strong>Results: </strong>Twenty-two articles met eligibility criteria. Of which, 82% (n = 18) were published in or after 2020. Fourteen studies (about 64%) followed the AHA's framework to conceptualize ideal CVH. Higher scores on ideal CVH are linked to better cardiovascular outcomes among cancer survivors with associations noted for social inequalities and neighborhood environmental factors, underscoring the complexity of CVH determinants in this population.</p><p><strong>Conclusions: </strong>Research on ideal CVH among cancer survivors appears to have accelerated in recent years, yet many gaps remain to orient clinical and public health practice. Promising research directions include expanding investigations into pre-diagnosis CVH, addressing disparities in CVH across diverse populations, and conducting longitudinal studies to clarify causal pathways between lifestyle behaviors, cancer treatments, and cardiovascular outcomes.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"11 1","pages":"34"},"PeriodicalIF":3.2,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956365/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune checkpoint inhibitors and myocarditis in advanced non-small cell lung cancer: a nationwide cohort study.","authors":"Fu-Xiao Li, Jia-Xin Cai, Ji-Bin Li, Kong-Jia Luo, Shi-Yu Wang, Wei-Hua Meng, Feng Sha, Zhi-Rong Yang, Allan Hackshaw, Jin-Ling Tang","doi":"10.1186/s40959-025-00325-6","DOIUrl":"10.1186/s40959-025-00325-6","url":null,"abstract":"<p><strong>Objective: </strong>Evidence suggests immune checkpoint inhibitor (ICI) can increase the risk of myocarditis. We investigated it in a large national cohort in China.</p><p><strong>Methods: </strong>Patients with stage IIIB-IV non-small cell lung cancer (NSCLC) using data from China's National Anti-Tumor Drug Surveillance System between January 2013 and December 2021. Exposure density sampling was applied to control for immortal time bias. Multivariate Cox regression with time-dependent exposures was used to examine the association between ICI therapy and the incidence of myocarditis while controlling for confounders.</p><p><strong>Results: </strong>55,219 patients were included. The median age was 61 years, and 62% were males. At one-year follow-up (median 335 days), there were 26 cases of myocarditis among ICI users and 28 cases among ICI non-users (a cumulative incidence of 4.8 and 0.6 per 1000 person-years respectively). The adjusted hazard ratio (HR) of myocarditis for ICI users was 7.41 (95% confidence interval [CI]: 3.29-16.67). For programmed cell death protein 1 inhibitor users the HR was 8.39 (95% CI: 3.56-19.77). No significant interactions were observed in subgroup analysis. The results remained unchanged in sensitivity analyses.</p><p><strong>Conclusions: </strong>This study showed that ICI therapy considerably increased the risk of myocarditis, supporting the need for closer monitoring of patients receiving ICI therapies.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"11 1","pages":"33"},"PeriodicalIF":3.2,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11956456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new online dynamic nomogram based on the inflammation burden index to predict cardiac injury after antitumor therapy in lung cancer patients.","authors":"Yumin Wang, Chunyan Huan, Huijuan Pu, Guodong Wang, Yan Liu, Xiuli Zhang, Chengyang Li, Jie Liu, Wanling Wu, Defeng Pan","doi":"10.1186/s40959-025-00328-3","DOIUrl":"10.1186/s40959-025-00328-3","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiotoxicity has become a major concern in cancer patients, especially those with lung cancer, as anti-tumor therapies can significantly affect patient survival and quality of life. This study aims to develop and validate a dynamic nomogram based on the Inflammation Burden Index (IBI) to predict the risk of cardiac injury within one year after anti-tumor treatment in lung cancer patients.</p><p><strong>Methods: </strong>This single-center, retrospective study included 1386 lung cancer patients who underwent myocardial enzyme testing between July 2018 and January 2023. The IBI was calculated as: IBI = (CRP (mg/dL) × Neutrophils (/μL)) / Lymphocytes (/μL). Statistical analysis using SPSS 22.0 and R 4.4.1, including machine learning algorithms and multivariate logistic analysis, identified independent predictors of cardiac injury. An online dynamic nomogram was developed and validated using internal validation, ROC curves, and decision curve analysis (DCA).</p><p><strong>Results: </strong>The average age of the 1386 patients was 61.98 ± 9.22 years. Significant independent predictors included age, BMI, hypertension, immunotherapy, D-dimer, LDH, NSE, CKMB, and IBI. The nomogram showed strong discriminative ability with AUC-ROC values of 0.85 for the training set and 0.86 for the validation set. Calibration curves confirmed good fit, and DCA showed high clinical utility.</p><p><strong>Conclusion: </strong>An online dynamic nomogram based on clinical and inflammatory markers was developed to predict cardiac injury in lung cancer patients following anti-tumor therapy. The model shows strong discriminative ability and potential clinical value, which can provide vital information for oncologists when designing customized clinical treatments.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"11 1","pages":"32"},"PeriodicalIF":3.2,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954219/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing cardiovascular risks with a goal to prevent cardiovascular complications in patients undergoing antihormonal therapy for prostate cancer.","authors":"Nishant P Shah, Avinash Singh, Tia Higano, Derya Tilki, Neil Fleshner, Paul Nguyen, Chris Plummer, Juan Gomez Rivas, Kathleen Zhang, Ricardo Rendon, Alicia Morgans, Filipe Cirne, Darryl Leong, Daniel Lenihan, Renato D Lopes","doi":"10.1186/s40959-025-00318-5","DOIUrl":"https://doi.org/10.1186/s40959-025-00318-5","url":null,"abstract":"<p><p>Over 1 million cases of prostate cancer are reported every year, and it is the second most common cancer in men. Androgen deprivation therapy (ADT) is a hallmark treatment for prostate cancer but is associated with the development or exacerbation of cardiovascular disease. The most common cause of non-cancer death in patients with prostate cancer is cardiovascular disease. Thus, a better understanding of the prevalence of cardiovascular toxicity across all therapies, management of potential cardiovascular complications, and prevention of cardiovascular events is essential as treatments continue to evolve. In this article, the first in a 2-part series, we provide a review of the current landscape of ADT therapy and its association with cardiovascular disease, summarize recent clinical trial data evaluating cardiovascular outcomes, and provide insights on the management of cardiovascular risk factors and adverse events for clinicians managing this high-risk population of men undergoing potentially cardiotoxic treatment for prostate cancer.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"11 1","pages":"31"},"PeriodicalIF":3.2,"publicationDate":"2025-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11954300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143742387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the diagnostic and prognostic value of criteria for immune checkpoint inhibitor related myocarditis.","authors":"Milagros Pereyra Pietri, Juan M Farina, Isabel G Scalia, Ahmed K Mahmoud, Michael Roarke, Beman Wasef, Cecilia Tagle-Cornell, Courtney R Kenyon, Mohammed Tiseer Abbas, Nima Baba Ali, Kamal A Awad, Niloofar Javadi, Nadera N Bismee, Carolyn M Larsen, Joerg Herrmann, Reza Arsanjani, Chadi Ayoub","doi":"10.1186/s40959-025-00327-4","DOIUrl":"10.1186/s40959-025-00327-4","url":null,"abstract":"<p><strong>Background: </strong>Myocarditis is a dreaded complication of immune-checkpoint inhibitor (ICI) therapy but challenging to diagnose. There are no published data comparing the two leading diagnostic criteria for ICI-related myocarditis (ICIrM) and their association with cardiovascular events.</p><p><strong>Methods: </strong>In this retrospective cohort study, we reviewed all patients who underwent ICI therapy and had cardiac troponin assessment for possible myocarditis across three tertiary institutions from 2011 to 2022. ICIrM was adjudicated by the Bonaca et al. criteria and the ESC-ICOS guidelines. A propensity matched control group was identified of patients treated with ICI without developing myocarditis. Baseline characteristics and long-term outcomes, including cardiac death, MACE (myocardial infarction, TIA/stroke, heart failure), and arrhythmias data were curated, and patients diagnosed with ICIrM by each criteria were compared to controls for cardiovascular events.</p><p><strong>Results: </strong>A total of 59 patients (mean age was 73.1 ± 10.2 years, 60.1% male) were identified as having a diagnosis of ICIrM by Bonaca criteria (16 definite, 13 probable and 30 possible myocarditis). Forty-seven of these patients met the ESC-ICOS guidelines criteria, and all patients meeting either set of ICIrM criteria were treated with steroid therapy. At 3-year follow up, patients diagnosed with ICIrM by the Bonaca criteria had a high risk of cardiac mortality (HR 17.84, 95%CI 2.36-134.62, p = 0.005), MACE (HR 4.90, 95%CI 2.40-10.02, p < 0.001) and arrhythmias (HR 3.33, 95%CI 1.78-6.21, p < 0.001) when compared to matched controls. ICIrM by ESC-ICOS criteria was similarly predictive of cardiac mortality, MACE, and arrhythmias (HR 15.01, 95%CI 1.96-114.76, p = 0.009, HR 5.18, 95%CI 2.33-11.53, p < 0.001, and HR 3.41, 95%CI 1.73-6.70, p < 0.001 respectively).</p><p><strong>Conclusion: </strong>The ESC-ICOS guidelines were more restrictive than the Bonaca et al. criteria for the diagnosis of ICIrM but similar in terms of prognostic value.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"11 1","pages":"30"},"PeriodicalIF":3.2,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11948924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}